Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci

Simple item page
dc.contributor.authorMunita, José
dc.contributor.authorMurray, Barbara
dc.contributor.authorArias, Cesar
dc.date.accessioned2017-04-05T14:46:19Z
dc.date.available2017-04-05T14:46:19Z
dc.date.issued2014
dc.description.abstractTreatment of severe infections caused by vancomycin-resistant enterococci (VRE) is challenging due to the scarcity of reliable therapeutic alternatives. In this context, daptomycin (DAP), a lipopeptide antibiotic, has emerged as an interesting alternative as it is one of the few compounds that retain in vitro bactericidal activity against VRE isolates, although it has not been approved for this purpose by regulatory agencies. In this review, we will summarise the clinical, animal and in vitro evidence evaluating the efficacy of DAP for the management of deep-seated VRE infections. In addition, we will address important clinical concerns such as the emergence of DAP resistance during therapy and reports of therapeutic failure with DAP monotherapy. Finally, we will discuss possible future strategies (such as the use of higher doses and/or combination therapies) to optimise the use of this antibiotic against VRE.
dc.format.extent9
dc.identifier.citationInt J Antimicrob Agents. 2014 Nov;44(5):387-395
dc.identifier.urihttp://hdl.handle.net/11447/1090
dc.identifier.urihttp://dx.doi.org/10.1016/j.ijantimicag.2014.08.002
dc.language.isoen_US
dc.publisherElsevier
dc.subjectDaptomycin
dc.subjectVRE
dc.subjectEnterococcal bacteraemia
dc.subjectEnterococci
dc.titleDaptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci
dc.typeArtículo

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.pdf
Size:
204.77 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services